A phase I study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of KH617 for patients with advanced solid tumors (including diffuse gliomas of adulthood).

KH617 - Chengdu Kanghong Pharma

https://www.asco.org/abstracts-presentations/259130

Wenbin Li; Zhuang Kang; Shenglan Li; Manxi Zhao; Yan Li; Wenguo Yin; Xiao Ke

Apr 21, 2026